PMID- 25518512
OWN - NLM
STAT- MEDLINE
DCOM- 20150210
LR  - 20141218
IS  - 0040-3660 (Print)
IS  - 0040-3660 (Linking)
VI  - 86
IP  - 9
DP  - 2014
TI  - [Role of eosinophil granulocytes in the occurrence of restenosis in patients 
      after coronary stenting with drug-eluting stents].
PG  - 90-6
AB  - AIM: To study the role of eosinophil granulocytes in the development of 
      restenosis after drug-eluting stent (DES) implantation. MATERIALS AND METHODS: 
      The blood levels of eosinophils, eosinophil cationic protein (ECP), 
      immunoglobulin E (IgE), and C-reactive protein (CRP) were compared in 170 
      patients with coronary heart disease (CHD) and stable angina who had undergone 
      recoronarography within the first year after endovascular myocardial 
      revascularization using DES. The blood level of eosinophils was determined by the 
      results obtained employing the FACS Calibur flow cytofluorometer (Becton 
      Dickinson, USA). That of ECP, IgE, and CRP was estimated by enzyme immunoassay by 
      means of an Immulite-100 analyzer (Siemens, Germany). The data were presented as 
      median (25th percentile and 75th percentile). RESULTS: The blood eosinophil level 
      was 272 (234; 292) cells/mul in patients with restenosis while that was 134 (85; 
      156) cells/mul in those without restenosis (p = 0.002). The plasma ECP level 
      proved to be greater in the patients who had developed restenosis after DES 
      implantation than in those who had not [17.7 (11.2; 24) and 9 (6.4; 12.9) ng/ml, 
      respectively (p = 0.017). At 6 months after DES implantation, the level of ECP 
      was significantly higher (8.6 (7.3; 9.7) ng/ml) than the baseline level (p = 
      0.04). Later on, there was an even greater increase in ECP levels. No significant 
      changes were noted in blood ECP levels after bare stent implantation. CONCLUSION: 
      The findings suggest that there is a relationship between the occurrence of 
      restenosis and the enhanced activity of eosinophil granulocytes in CHD patents 
      after DES implantation.
FAU - Gabbasov, Z A
AU  - Gabbasov ZA
FAU - Kozlov, S G
AU  - Kozlov SG
FAU - Imaeva, A E
AU  - Imaeva AE
FAU - Saburova, O S
AU  - Saburova OS
FAU - Masenko, V P
AU  - Masenko VP
LA  - rus
PT  - English Abstract
PT  - Journal Article
PL  - Russia (Federation)
TA  - Ter Arkh
JT  - Terapevticheskii arkhiv
JID - 2984818R
RN  - 0 (Immunosuppressive Agents)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angioplasty, Balloon, Coronary/*adverse effects/instrumentation/methods
MH  - C-Reactive Protein/analysis
MH  - Coronary Angiography
MH  - Coronary Artery Disease/*therapy
MH  - *Coronary Restenosis/blood/etiology/pathology
MH  - Drug-Eluting Stents/*adverse effects
MH  - Eosinophil Cationic Protein/blood
MH  - *Eosinophils/metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Immunosuppressive Agents/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Sirolimus/pharmacology
MH  - Statistics as Topic
EDAT- 2014/12/19 06:00
MHDA- 2015/02/11 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/02/11 06:00 [medline]
PST - ppublish
SO  - Ter Arkh. 2014;86(9):90-6.